Header Logo

Connection

Tammy Meyers to Humans

This is a "connection" page, showing publications Tammy Meyers has written about Humans.
Connection Strength

0,814
  1. Dolutegravir for children with HIV-associated tuberculosis. Lancet HIV. 2022 09; 9(9):e599-e600.
    View in: PubMed
    Score: 0,064
  2. Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. AIDS. 2019 11 15; 33(14):2197-2203.
    View in: PubMed
    Score: 0,053
  3. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa. Pediatr Infect Dis J. 2015 Feb; 34(2):175-9.
    View in: PubMed
    Score: 0,038
  4. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. AIDS. 2013 Mar 13; 27(5):781-5.
    View in: PubMed
    Score: 0,033
  5. Positive association between dietary iron intake and iron status in HIV-infected children in Johannesburg, South Africa. Nutr Res. 2013 Jan; 33(1):50-8.
    View in: PubMed
    Score: 0,033
  6. Changes in pediatric HIV-related hospital admissions and mortality in Soweto, South Africa, 1996-2011: light at the end of the tunnel? J Acquir Immune Defic Syndr. 2012 Aug 15; 60(5):503-10.
    View in: PubMed
    Score: 0,032
  7. Neurodevelopmental delay among HIV-infected preschool children receiving antiretroviral therapy and healthy preschool children in Soweto, South Africa. Psychol Health Med. 2012; 17(5):599-610.
    View in: PubMed
    Score: 0,031
  8. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. Pediatr Infect Dis J. 2011 Nov; 30(11):974-9.
    View in: PubMed
    Score: 0,030
  9. Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents. Paediatr Drugs. 2011 Oct 01; 13(5):303-16.
    View in: PubMed
    Score: 0,030
  10. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One. 2011 Feb 23; 6(2):e17273.
    View in: PubMed
    Score: 0,029
  11. Case records of the Massachusetts General Hospital. Case 18-2010. A 7-year-old boy with elevated HIV RNA levels despite antiretroviral medications. N Engl J Med. 2010 Jun 17; 362(24):2305-12.
    View in: PubMed
    Score: 0,028
  12. Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS. 2010 Jun 01; 24(9):1341-9.
    View in: PubMed
    Score: 0,027
  13. Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. AIDS. 2010 Jan 02; 24(1):139-46.
    View in: PubMed
    Score: 0,027
  14. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis. 2009 Jul; 13(7):862-7.
    View in: PubMed
    Score: 0,026
  15. Challenges to pediatric HIV care and treatment in South Africa. J Infect Dis. 2007 Dec 01; 196 Suppl 3:S474-81.
    View in: PubMed
    Score: 0,023
  16. Ultrasensitive human immunodeficiency virus type 1 p24 antigen assay modified for use on dried whole-blood spots as a reliable, affordable test for infant diagnosis. Clin Vaccine Immunol. 2006 Jan; 13(1):152-5.
    View in: PubMed
    Score: 0,020
  17. Socioemotional and behavioural difficulties in children with chronic physical conditions: analysis of the Longitudinal Study of Australian Children. Arch Dis Child. 2023 07; 108(7):569-575.
    View in: PubMed
    Score: 0,017
  18. Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. J Pediatric Infect Dis Soc. 2021 Mar 26; 10(2):201-204.
    View in: PubMed
    Score: 0,015
  19. T-helper cell responses among HIV-infected children in Soweto, South Africa. Ann N Y Acad Sci. 2000 Nov; 918:373-6.
    View in: PubMed
    Score: 0,014
  20. HIV infection and in-hospital mortality at an academic hospital in South Africa. Arch Dis Child. 2000 Sep; 83(3):227-30.
    View in: PubMed
    Score: 0,014
  21. Pediatric admissions with human immunodeficiency virus infection at a regional hospital in Soweto, South Africa. J Trop Pediatr. 2000 08; 46(4):224-30.
    View in: PubMed
    Score: 0,014
  22. Age-specific and sex-specific weight gain norms to monitor antiretroviral therapy in children in low-income and middle-income countries. AIDS. 2015 Jan 02; 29(1):101-9.
    View in: PubMed
    Score: 0,009
  23. Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa. Int J Tuberc Lung Dis. 2014 Jun; 18(6):676-81.
    View in: PubMed
    Score: 0,009
  24. Effect of baseline immune suppression on growth recovery in HIV positive South African children receiving antiretroviral treatment. J Acquir Immune Defic Syndr. 2012 Oct 01; 61(2):235-42.
    View in: PubMed
    Score: 0,008
  25. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Aug 01; 60(4):369-76.
    View in: PubMed
    Score: 0,008
  26. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
    View in: PubMed
    Score: 0,008
  27. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. Eur J Clin Pharmacol. 2012 Apr; 68(4):339-47.
    View in: PubMed
    Score: 0,008
  28. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011 Jul 31; 25(12):1461-9.
    View in: PubMed
    Score: 0,007
  29. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
    View in: PubMed
    Score: 0,007
  30. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis. 2011 Feb 15; 52(4):514-21.
    View in: PubMed
    Score: 0,007
  31. Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr. 2011 Jan 01; 56(1):9-15.
    View in: PubMed
    Score: 0,007
  32. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther. 2011; 16(3):417-21.
    View in: PubMed
    Score: 0,007
  33. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1510-20.
    View in: PubMed
    Score: 0,007
  34. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010 Sep 08; 304(10):1082-90.
    View in: PubMed
    Score: 0,007
  35. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. AIDS Res Hum Retroviruses. 2010 Jun; 26(6):613-9.
    View in: PubMed
    Score: 0,007
  36. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis. 2010 Apr 15; 201(8):1121-31.
    View in: PubMed
    Score: 0,007
  37. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 2009 Jun 01; 23(9):1097-107.
    View in: PubMed
    Score: 0,006
  38. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2009 Apr 15; 50(5):439-43.
    View in: PubMed
    Score: 0,006
  39. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15; 48(4):462-72.
    View in: PubMed
    Score: 0,006
  40. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008 Apr 15; 47(5):566-9.
    View in: PubMed
    Score: 0,006
  41. 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol. 2008 Mar; 82(5):2367-75.
    View in: PubMed
    Score: 0,006
  42. Evaluation of the ultrasensitive human immunodeficiency virus type 1 (HIV-1) p24 antigen assay performed on dried blood spots for diagnosis of HIV-1 infection in infants. Clin Vaccine Immunol. 2008 Feb; 15(2):388-91.
    View in: PubMed
    Score: 0,006
  43. The utility of fine needle aspiration in HIV positive children. Cytopathology. 2008 Apr; 19(2):86-93.
    View in: PubMed
    Score: 0,006
  44. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr. 2007 Jun 01; 45(2):133-6.
    View in: PubMed
    Score: 0,006
  45. Surgeons are failing to recognize children with HIV infection. J Pediatr Surg. 2007 Feb; 42(2):431-4.
    View in: PubMed
    Score: 0,005
  46. Polymorphisms in Nef associated with different clinical outcomes in HIV type 1 subtype C-infected children. AIDS Res Hum Retroviruses. 2007 Feb; 23(2):204-15.
    View in: PubMed
    Score: 0,005
  47. Evaluation of dried whole blood spots obtained by heel or finger stick as an alternative to venous blood for diagnosis of human immunodeficiency virus type 1 infection in vertically exposed infants in the routine diagnostic laboratory. Clin Vaccine Immunol. 2007 Feb; 14(2):201-3.
    View in: PubMed
    Score: 0,005
  48. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 2006 Jul; 3(7):e255.
    View in: PubMed
    Score: 0,005
  49. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses. 2006 May; 22(5):458-65.
    View in: PubMed
    Score: 0,005
  50. Barriers to disclosure to children with HIV. J Trop Pediatr. 2005 Oct; 51(5):285-7.
    View in: PubMed
    Score: 0,005
  51. Detection of human immunodeficiency virus type 1 envelope peptide- stimulated T-helper cell responses and variations in the corresponding regions of viral isolates among vertically infected children. Virus Genes. 2004 Apr; 28(3):311-8.
    View in: PubMed
    Score: 0,004
  52. Full-length genome characterization of HIV type 1 subtype C isolates from two slow-progressing perinatally infected siblings in South Africa. AIDS Res Hum Retroviruses. 2003 Nov; 19(11):1033-7.
    View in: PubMed
    Score: 0,004
  53. Human immunodeficiency virus type 1 envelope-stimulated interleukin-2 production and survival of infected children with severe and mild clinical disease. J Infect Dis. 2001 Sep 15; 184(6):691-8.
    View in: PubMed
    Score: 0,004
  54. Interleukin-8 concentrations in the peripheral circulation of human immunodeficiency virus type 1-infected children suggest blunted chemokine responses. Pediatr Infect Dis J. 2001 Aug; 20(8):819-20.
    View in: PubMed
    Score: 0,004
  55. Altered expression of L-selectin (CD62L) on polymorphonuclear neutrophils of children vertically infected with human immunodeficiency virus type 1. J Clin Immunol. 2001 Jul; 21(4):286-92.
    View in: PubMed
    Score: 0,004
  56. Defective neutrophil degranulation induced by interleukin-8 and complement 5a and down-regulation of associated receptors in children vertically infected with human immunodeficiency virus type 1. Clin Diagn Lab Immunol. 2001 Jan; 8(1):21-30.
    View in: PubMed
    Score: 0,004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.